Globe Life Inc. Issues Statement Refuting False Short Seller Report
Get Alerts GL Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.8%
EPS Growth %: +12.2%
Join SI Premium – FREE
Following the rapid onset of the pandemic, American Income Life (AIL) and its independent agency owners began transitioning to a virtual business model, which in turn led many agency owners to realign their real estate portfolios. By enabling our agents to work virtually, providing work flexibility and eliminating overhead costs to better build their own businesses, AIL's agent count increased from over 8,000 agents in March of 2020 to over 12,000 in November of 2024. This virtual business model has helped enable the Globe Life family of companies to issue more life insurance policies and protect more policyholders than any other life insurance company in the country, with more than 17 million policies in force.
Once again, an opportunistic short seller has presented a false picture of AIL's presence across the country. To be clear, every single business named in the report is still in operation. We verified that the report listing of disconnected phone numbers is inaccurate and misleading. These independent agency offices operate from various virtual and physical locations, allowing agents to service customers across the country more efficiently. The short seller's misrepresentation of our strategy is yet another dishonest and cynical effort to harm the Company's reputation, manufacture a drop in the stock price, and reap a short-term profit at the expense of our people, our investors, and the millions of individuals and families we protect.
Media Contact:
Executive Vice President and Chief Marketing Officer
[email protected]
Investor Contact:
Stephen Mota
Senior Director Investor Relations
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/globe-life-inc-issues-statement-refuting-false-short-seller-report-302322954.html
SOURCE Globe Life
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formu
- Costerfield – True Blue Exploration Update
- Startup Island TAIWAN Bridges Tech Hubs, Launching East Coast Biotech Initiative in Boston
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share